Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 18Recruiting 11Withdrawn 2Active not recruiting 2Unknown 1Suspended 1Not yet recruiting 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Oligodendroglioma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Carboplatin 127Cisplatin 125Drug Therapy 116Bevacizumab 102Capecitabine 100Oxaliplatin 99Radiotherapy 97Gemcitabine 87tislelizumab 86Paclitaxel 86Cyclophosphamide 85pembrolizumab 77Specimen Handling 77toripalimab 70Magnetic Resonance Spectroscopy 63Injections 63Fluorouracil 63sintilimab 58Surgical Procedures, Operative 58anlotinib 53Docetaxel 52130-nm albumin-bound paclitaxel 51fludarabine 47Standard of Care 45Pemetrexed 45Immune Checkpoint Inhibitors 45Blood Specimen Collection 43venetoclax 42Leucovorin 42lenvatinib 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Eflornithine × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡